Anyway, lets try to get beyond the usual crap and back to Cynata,
The deal coverage was of course in the Market Herald, Hot Copper's attempt to move beyond the usual retail exuberance, or troll fueled gloom of its threads towards actual investment news:
https://themarketherald.com.au/cynata-therapeutics-asxcyp-granted-funding-for-kidney-transplantation-clinical-trial-2022-11-02/It also made Stock-Head, which Hot Copper will no doubt HC will blank out when I post, as a rival:
https://**promotion blocked**/health/asx-biotech-stocks-hitiq-nabs-landmark-deal-with-premier-league-for-its-concussion-management-tech/I would remind everyone again, the LUMC has been a bit of a pioneer amongst learning centres in stem cells:
https://www.universiteitleiden.nl/en/news/2021/12/300-million-euros-for-new-international-stem-cell-consortiumWhilst the trial is a small one,
it is a huge accolade that LUMC is funding this trial and selected CYP amongst all the candidates. I don't mean to be rude to Hot Copper posters, but I will side with their assessment before I do a load of well, but less, informed trolls on HC. CYP is going to require patience of course, but its a bargain down here relative to its trials and standing in the stem-cell sector.
(20min delay)